Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

This study will compare the results of stem cell mobilization using drugs called filgrastim
(Neupogen) and plerixafor with the results of stem cell mobilization using drugs called XM02
filgrastim (Granix) and plerixafor. The FDA has determined that Granix is biosimilar to
Neupogen, which means that they are similar in terms of quality, safety, and efficacy;
however, Granix has not been tested in the context of stem cell mobilization to see how its
effectiveness compares to that of Neupogen

Inclusion Criteria:

- At least 18 years of age

- Diagnosis of multiple myeloma or non-Hodgkin lymphoma

- Eligible for autologous transplantation

- Adequate bone marrow function as defined as:

- White Blood Cell Count ≥ 3.0x109/L

- Absolute Neutrophil Count ≥ 1.5x109/L

- Platelet Count ≥ 100x109/L

- Able to understand and willing to sign an IRB-approved informed consent document

- Surgically or biologically sterile or willing to practice acceptable birth control, as
follows:

- Women of childbearing potential must have a negative serum or urine pregnancy
test within 7 days of Day 1 of study treatment. Women of childbearing potential
must agree to abstain from sexual activity or use a medically approved
contraceptive measure/regimen during and for 3 months after the treatment period.
Acceptable methods of birth control include: barriers (condoms), oral
contraceptive, intrauterine device (IUD), transdermal/implanted or injected
contraceptives, and abstinence

- Males must agree to abstain from sexual activity or agree to utilize a medically
approved contraception method during and for 3 months after the treatment period.
Acceptable methods of birth control include: barriers (condoms), oral
contraceptive, intrauterine device (IUD), transdermal/implanted or injected
contraceptives, and abstinence

Exclusion Criteria:

- Previous autologous stem cell collection

- Known hypersensitivity to filgrastim, plerixafor, or E. coli derived products

- Pregnant or breastfeeding